SYNMOSA Business Summary

Synmosa Biopharma Corp. (4114.TWO) is a leading Taiwan-based specialty pharmaceutical company that operates a vertically integrated business model encompassing R&D, PIC/S GMP-certified manufacturing, and global distribution. The company generates revenue primarily through the sale of generic drugs, active pharmaceutical ingredients (APIs), and high-threshold specialty products, supplemented by contract manufacturing (OEM) and strategic licensing alliances with global partners like Zai Lab and CStone Pharmaceuticals. Its primary business segments are categorized by therapeutic focus, including respiratory, cardiovascular, urology, sex hormones, and oncology, with a competitive edge derived from niche technology platforms such as metered-dose inhalers (MDI), nasal sprays, and effervescent tablets. Synmosa maintains a robust market position in Taiwan's specialist medical channels and is currently executing its "2030 Vision" to expand into a dominant regional player across Asia, competing directly with major domestic peers such as YungShin Global Holding, ScinoPharm Taiwan, TTY Biopharm, and Standard Chemical & Pharmaceutical. The company was founded in 1980 by Peter Lin (Lin Chih-hui), who continues to lead the organization as Chairman, CEO, and President. A graduate of Taipei Medical University with over 40 years of industry experience, Lin has overseen Synmosa’s transformation from a local distributor into a diversified pharmaceutical group through aggressive M&A and strategic partnerships. The executive leadership team includes Senior Vice President and Spokesman Pai Hung-chin, who manages financial operations, and Chief Financial Officer Huang Liyu. The company’s technical and commercial strategies are further supported by a seasoned board and senior vice presidents Jia-Xin Zhang and Sheng-Ren Yang. Notable institutional backing includes positions held by global investment firms such as Vanguard, DFA Investment Dimensions Group, and Dimensional Emerging Markets Value Fund, reflecting the company's stable financial standing and growth trajectory in the regional healthcare sector.